wahr oder falsch fragen
Median PFS was calculated using the Kaplan-Meier technique. Clinical trials on tremelimumab have been conducted on cancer patients in an attempt to study the prevention, detection, or treatment of multiple diseases. Tremelimumab is a fully human monoclonal antibody against CTLA-4. If a patient did not progress following a response, then their DoR was censored at the progression-free survival (PFS) censoring time. Location: 2 locations, The main purpose of this study is to determine the anti-tumor activity of durvalumab in combination with tremelimumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This trial is being done to see whether brachytherapy with durvalumab or tremelimumab works better in treating patients with gynecological malignancies. The purpose of this pilot clinical trial was to test the antitumor and antiviral effect of tremelimumab in patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) … PFS during the retreatment phase was assessed by the site Investigator using RECIST 1.1 and defined as the time from the date of enrollment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the patient withdrew from therapy or received another anticancer therapy prior to progression. Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York, This phase II trial studies the side effects and how well brachytherapy with durvalumab or tremelimumab work for the treatment of gynecological malignancies that is resistant to platinum therapy (platinum-resistant), does not respond to treatment (refractory), has come back (recurrent), or has spread to other places in body (metastatic). Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors: Actual Study Start Date : November 26, 2014: Actual Primary Completion Date : December 8, 2017: Actual Study Completion Date : March 5, 2018 Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Location: 2 locations, This phase II trials studies the side effects and best dose of durvalumab and radiation therapy with or without tremelimumab in treating patients with stage III non-small cell lung cancer that can be removed by surgery. This is an open-label, multi-center study to determine the efficacy and safety of tremelimumab in the treatment of different cohorts of patients with selected advanced solid tumors. The goal of this clinical trial is to test the safety and the effectiveness of both durvalumab and tremelimumab. Talk to your doctor for help in deciding if one is right for you. For general information, Learn About Clinical Studies. Clinical Trials. Tremelimumab blocks the activity of CTLA-4, contributing to T cell activation and boosting the immune response to cancer. Location: 8 locations, This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra). Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, Complementary & Alternative Medicine (CAM), Coping with Your Feelings During Advanced Cancer, Late Effects of Childhood Cancer Treatment, Frederick National Laboratory for Cancer Research, Milestones in Cancer Research and Discovery, Tech Transfer & Small Business Partnerships, Step 1: Application Development & Submission, How to Work With Your Health Insurance Plan, Questions to Ask about Treatment Clinical Trials, Drugs Approved for Different Types of Cancer, Drugs Approved for Conditions Related to Cancer, Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer, Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy, Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma, Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer, Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, Tremelimumab in Treating Patients with Previously Treated Metastatic Urothelial Cancer, Durvalumab and Tremelimumab in Treating Patients with Relapsed or Refractory Germ Cell Tumors, Durvalumab, an Anti-PDLI Antibody, Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation before Surgery for Esophageal Cancer, A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers, Durvalumab and Tremelimumab for Pediatric Malignancies, Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma or Biliary Tract Cancer, Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with High Risk Soft-Tissue Sarcoma, Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants with Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers, Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Gynecologic Cancer That Is Metastatic or Cannot Be Removed by Surgery, Durvalumab and Radiation Therapy with or without Tremelimumab in Treating Patients with Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery, Durvalumab and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, Durvalumab and Tremelimumab in Treating Patients with Metastatic HER2 Negative Breast Cancer, Durvalumab and Tremelimumab for the Treatment of Stage II-IIIB Non-small Cell Lung Cancer, Brachytherapy with Durvalumab or Tremelimumab for the Treatment of Patients with Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies, Durvalumab and Tremelimumab in Combination with Platinum-based Chemotherapy for the Treatment of Patients with Untreated Extensive-Stage Small Cell Lung Cancer, Durvalumab with or without Tremelimumab or Olaparib after Thoracic Radiation Therapy in Treating Patients with Extensive Stage-Small Cell Lung Cancer, Durvalumab and Tremelimumab in Treating Patients with Somatically Hypermutated Recurrent or Refractory Solid Tumors, Durvalumab and Tremelimumab in Treating Patients with Liver Cancer Undergoing Drug-Eluting Bead Transarterial Chemoembolization, Stereotactic Body Radiation Therapy and Durvalumab with or without Tremelimumab before Surgery in Treating Patients with Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner, Radiation Therapy and Durvalumab with or without Tremelimumab in Treating Participants with Unresectable, Locally Advanced, or Metastatic Bladder Cancer, U.S. Department of Health and Human Services. The BoR was summarized by percentage of patients for each category (CR, PR, SD, PD, and NE). Location: 20 locations, This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy This clinical trial studies the effect of durvalumab and tremelimumab in treating patients with stage II-IIIB non-small cell lung cancer who have undergone surgical removal and completed after surgery treatment with or without radiation therapy and now have detectable tumor DNA in the blood. U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The first time you have the drugs there will be a 1 hour gap between MEDI4736 and tremelimumab. Objective response rate (ORR) during the initial tremelimumab monotherapy phase was assessed by the site Investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and was defined as the percentage of patients with a confirmed overall response of complete response (CR) or partial response (PR) and was based on all treated patients who had measurable disease at baseline (Day 1). Giving durvalumab together with chemotherapy and radiation therapy before surgery may work better at treating patients with esophageal or gastroesophageal junction cancer. Median DoR was calculated using the Kaplan-Meier technique. Location: 12 locations, This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. Please remove one or more studies before adding more. Median PFS was calculated using the Kaplan-Meier technique. DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event. Talk with your doctor and family members or friends about deciding to join a study. Median OS was calculated using the Kaplan-Meier technique. Both durvalumab and tremelimumab may help strengthen the immune system. 95% CIs were calculated using the Clopper Pearson method. Design, setting, and participants: Part A of this multicenter, 2-part, phase 2 randomized clinical trial was a lead-in safety, open-label study with planned expansion to part B pending an efficacy signal from part A.
Gottes Hilfe In Finanzieller Not, Mister Minit Batteriewechsel Kosten, Led Soffitte Vw T5, Bilder Zur Geburt Eines Jungen, übergabeprotokoll Kassierer Verein,